David Peltier is a research associate at TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Peltier appreciates your feedback; click here to send him an email.

If you liked this article you might like

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Mallinckrodt Inks $1.3B Deal for Cadence

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Biotech Stocks Partying Like It's 1999

8 Stocks Under $10 Trending Sharply Higher